M

Mass General Brigham

Early-stage life science venture investor

Registered Nurse

Part-TimeUpdated on 10/23/2026
$45.52 - $110/hr+ Differentials + Premiums + Bonuses
Senior
Bachelor's
Newton, MA, USA
In PersonOnsite at 2014 Washington Street.
Medical, Clinical & VeterinaryNursing & Frontline Patient Care

About the job

Requirements
  • A nursing certificate or diploma is required; a Bachelor's Degree in Nursing is preferred, and experience cannot substitute for a degree.
  • A current state Registered Nurse license is required.
  • Experience and certifications or advanced training required by the applicable specialty are required; specialty certifications or advanced training are preferred.
  • Strong interpersonal communication, problem-solving, and conflict-management skills are required.
  • Demonstrated clinical competence and experience as required by the specific job posting are required.
  • The applicable specialty-specific experience and credentials include: Adult GI requires two years of critical care or GI experience; ACLS within the first year is required and CCGRN certification is preferred. ARTC requires a BSN upon employment, completion of the ASRM RN certificate course within the first year, and at least one year working in reproductive endocrinology. Cancer Center requires at least one year administering single-agent and multidrug chemotherapy in an outpatient setting, assessment skills, knowledge of hematology/oncology pathophysiology and treatment side effects, medical oncology nursing knowledge and experience, Oncology Nursing Certification (OCN) or completion within the first year, and a Chemotherapy/Biotherapy Administration Certification Card; three years of ambulatory oncology nursing experience and Oncology Nursing Society membership are strongly preferred. Cardiovascular Center requires two years of critical care experience and previous interventional radiology and/or electrophysiology experience; BLS and ACLS are required upon employment, while cardiac ICU, CCU, cardiac surgery, or cath lab experience and proficiency in IV catheter insertion and IV sedation in an acute procedural setting are preferred. Device Clinic requires two years of device clinic experience with pacemaker programming and clinic follow-up, BCLS, and ACLS; HRS/NASP certification is preferred. ED requires two years of ED experience and ACLS, PALS, and CPI within the first year; CEN or CCRN is preferred. ICU requires two years of critical care experience and ACLS within the first year. Labor & Delivery/AETU requires two years of L&D experience and NRP within the first year; fetal monitoring experience is preferred. Maternal Fetal Medicine requires at least two years of clinical experience in perinatal services, at least one year working in reproductive endocrinology, a BSN, and BLS before hire; ACLS is preferred. Med/Surg requires one year of Med/Surg experience; telemetry experience is preferred, and telemetry training is required within the first year. Mother/Baby requires two years of mother/baby experience and NRP within the first year; fetal monitoring experience is preferred. OR requires two years of OR experience; completion of a peri-operative nursing program and AORN certification are preferred. PACU/Henderson requires two years of critical care/PACU experience; PACU requires ACLS and PALS within the first year, and CPAN/CAPA certification is preferred. Pediatrics requires two years of pediatrics experience; NRP is required within the first year when cross-trained for mother/baby. Pedi GI requires two years of Pedi GI experience and PALS within the first year. Psychiatry requires two years of psychiatry experience and CPI within the first month. SCN requires two years of SCN experience and NRP within the first year. STAT RN requires two years of critical care/emergency nursing experience and ACLS, PALS, and CPI within the first year. Primary Care Triage RN requires two years of triage, ER, urgent care, or outpatient experience; ambulatory care nursing certification ANCC RN-BC is preferred.
  • The role requires ability to use the nursing process and evidence-based practice, maintain a safe therapeutic environment, participate in performance improvement, communicate patient information accurately and promptly, administer medication and IV therapy safely, and coordinate with multidisciplinary teams to develop patient education plans.
  • The role requires work in patient-care environments with possible exposure to communicable diseases and hazardous materials, including chemotherapeutic agents, radioisotopes, and radiation; human waste and other unpleasant conditions; cleaning tasks involving dirt, odors, and cramped quarters; and potentially angry, agitated, or combative patients.
Responsibilities
  • Provide professional and technical nursing care to assigned patients using the nursing process, including assessment, planning, implementation, and evaluation.
  • Provide direct and indirect patient care, oversee assigned team members, and collaborate with a multidisciplinary team to deliver population-specific care in accordance with applicable regulations and professional standards.
  • Use evidence-based practice to deliver quality care throughout the episode of care; assess patients’ physical, psychological, spiritual, cultural, and social needs and individualize care for each patient and population.
  • Apply knowledge of illness, injury, and disease to assess patients and recognize symptoms requiring immediate intervention; develop, update, implement, and evaluate individualized plans of care in collaboration with patients, families, and appropriate care-team members.
  • Engage patients and their families or significant others as partners in care, education, and discharge planning; coordinate resources and collaborate with case managers to anticipate discharge needs and address barriers.
  • Implement clinical and technical aspects of care and physicians’ orders in accordance with standards of practice and care; recognize changes in patient condition and inform the physician or another healthcare professional.
  • Maintain a safe and therapeutic environment; use patient identifiers, infection-control practices, universal precautions, OSHA standards, hazardous-material guidelines, isolation procedures, restraint alternatives, and fall precautions appropriately.
  • Protect confidential patient and personnel information, provide comfort and hygiene, use equipment and supplies correctly, perform point-of-care testing with proper technique and calibration, and ensure equipment is safe and operational.
  • Respond appropriately to emergencies, advocate for patients, provide emotional, psychological, and spiritual support, and treat patients and families respectfully and without judgment.
  • Participate in performance-improvement activities, evaluate care outcomes, apply recommendations, and suggest approaches to cost containment and efficient use of supplies and services.
  • Complete accurate, timely, and organized documentation of patient information, progress, medication records, and discharge instructions; communicate information across the continuum of care.
  • Administer medication and IV therapy safely and accurately; apply the five rights of medication administration, verify medication orders and infusion rates, use barcode scanning where applicable, and recognize and report medication variances and adverse reactions.
  • Assess patient and family education needs, develop and implement an education plan that accounts for learning barriers and cultural or spiritual needs, document education, and evaluate and revise instruction based on outcomes and feedback.
  • Maintain clinical competence and required training, accept accountability for assigned patient care, initiate changes that improve nursing care, and perform charge-nurse duties as needed.
  • Serve as a resource and professional role model for peers and students, assist with orientation and ongoing support of new staff, communicate expectations to assigned team members, and escalate care concerns through the chain of command.
  • For Device Clinic assignments, enroll, interrogate, and program outpatient pacemaker patients; identify abnormalities, malfunctions, and end-of-service indicators; notify cardiologists and coordinate follow-up or replacement; educate patients and families about device function and clinic follow-up; forward information to referring physicians; document and bill appropriately; lead the device recall team; administer trans-telephonic monitoring duties, including purchase orders, billing issues, and reporting; oversee Cardiac Arrhythmia Service event monitoring; provide cross-coverage; and contribute recommendations toward budgetary goals.
  • For STAT RN assignments, assist with rapid responses and Code Blue events; support admissions and transfers of critically ill patients to the ICU; assist with care of unstable or critically ill ICU-level patients in the ED, PACU, and medical-surgical units; assist with IV access, phlebotomy, and transport and supervision for diagnostic testing; provide ICU support when census or acuity exceeds core staffing and other resources are unavailable; and perform other clinical duties when critical-care support is not needed.
  • Perform other duties as assigned and work under the direct supervision of the Nursing Administrator and the overall direction of the ICU nurse manager for STAT RN assignments.
Desired Qualifications
  • For ARTC, demonstrate advanced knowledge of reproductive health and treatment options.
  • For Cancer Center, have three years of ambulatory oncology nursing experience and Oncology Nursing Society membership.
  • For Cardiovascular Center, have cardiac ICU, CCU, cardiac surgery, or cath lab experience and proficiency in IV catheter insertion and IV sedation in an acute procedural setting.
  • For Device Clinic, hold HRS/NASP certification.
  • For ED, hold CEN or CCRN certification.
  • For Labor & Delivery/AETU or Mother/Baby, have fetal monitoring experience.
  • For Maternal Fetal Medicine, hold ACLS.
  • For Med/Surg, have telemetry experience.
  • For OR, have completed a peri-operative nursing program and hold AORN certification.
  • For PACU/Henderson, hold CPAN/CAPA certification.
  • For Primary Care Triage RN, hold ambulatory care nursing certification ANCC RN-BC.

About the company

Mass General Brigham Ventures funds early-stage life science ideas arising from Mass General Brigham’s research network. It provides first access to deal flow and proprietary rights, backing the formation and growth of new companies and technologies. It uses capital and support to help translate bold innovations into drugs and medical technologies that improve patient outcomes worldwide.

Company Size

1-10

Company Stage

N/A

Total Funding

$1.9B

Headquarters

Cambridge, Massachusetts

Founded

2008

Get referred to Mass General Brigham

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Mass General Brigham reported $15 million operating income through June 30, 2026.
  • Outpatient growth and higher-acuity inpatient volumes drove 7% revenue growth in Q3 FY26.
  • Abcuro's 2026 financing extends a potential registrational trial, validating MGB Ventures sourcing.

What critics are saying

  • Brigham nurses authorized an indefinite strike on September 24, 2026; operations face disruption.
  • MGB refused negotiations after July strikes and lockouts, deepening staffing instability into 2027.
  • The September 2026 antidiscrimination case and website-data settlement reinforce litigation overhangs.

What makes Mass General Brigham unique

  • Mass General Brigham controls flagship Boston hospitals and a research-to-venture pipeline.
  • MGB Ventures backed Abcuro's $66 million Series D in August 2026.
  • Its $22.8 billion 2025 operating revenue funds clinical, academic, and commercialization depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Flexible Work Hours
  • Remote Work Options
  • Hybrid Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Family Planning Benefits
  • Fertility Treatment Support

Company News

Business Wire
Oct 25th, 2026
Nocion Therapeutics Extends Series B Financing to $93 Million to Support Late-Stage Development of Taplucainium in Chronic Cough

Nocion Therapeutics, Inc. today announced that it has raised $23 million from existing investors in an extension of its Series B, bringing the total amount o...

PR Newswire
Oct 1st, 2026
Mass General Brigham postpones annual summit after nurses plan picket over $2.3B hospital system refusing fair contracts

Mass General Brigham has postponed its annual summit after nurses and clinicians represented by the Massachusetts Nurses Association issued a picket notice for the 7 October event in Somerville. The postponement follows a 93% strike authorisation vote by Brigham and Women's Hospital nurses and protests against MGB executives. MGB nurses and clinicians have been campaigning against the hospital system following strikes and a lockout in July. Brigham nurses are seeking contract improvements including limits on temporary nurses, affordable health insurance, and fair compensation. MGB Home Care clinicians are negotiating their first union contract. MGB reported $22.8 billion in operating revenue and $2.39 billion in profits for fiscal year 2025. The system has refused to return to negotiations since August.

ABCuro
Aug 18th, 2026
Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis.

Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis. * Proceeds to support a potentially registrational clinical study in less severe inclusion body myositis (IBM) patients expected to begin in Q4 2026 and report top line results in 2H 2028 * Ulviprubart showed a trend toward clinically meaningful slowing of disease progression in patients with less severe IBM in the previous Phase 2/3 MUSCLE study * Series D financing led by New Leaf Venture Partners, joined by Abcuro's existing investors and new investor Rock Springs Capital Newton, Massachusetts, August 18, 2026 - Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases through precise modulation of cytotoxic T cells, today announced the closing of a $66 million Series D financing led by current investor New Leaf Venture Partners with participation of existing investors including funds managed by abrdn Inc., Bain Capital Life Sciences, Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital Management, Pontifax, Sanofi Ventures, Foresite Capital, NEA, Eurofarma Ventures, Kaitai Capital, Soleus Capital, Nancy Chang, Shang Bay and joining the round is Rock Springs Capital. Proceeds from the Series D financing will support a new potentially registrational clinical study of ulviprubart, a first-in-class monoclonal antibody targeting killer cell lectin like receptor G1 (KLRG1), for the treatment of patients with less severe IBM. Abcuro has been in discussions with the U.S. Food and Drug Administration (FDA) and expects to initiate the new study in the fourth quarter of this year. Assuming positive results from the clinical study, Abcuro plans to file a biologics license application (BLA). "We are pleased to have this opportunity to further evaluate ulviprubart in patients with IBM, a devastating progressive disease," said Alex Martin, Chief Executive Officer of Abcuro. "We have begun preparations to initiate a clinical trial in the fourth quarter of 2026 as we continue our work to develop an effective treatment option in an indication where there is no approved therapy. We remain dedicated to the IBM community and thank our investors who share our conviction in ulviprubart's potential." Results from the recent Phase 2/3 MUSCLE study of ulviprubart in patients with IBM were presented at the 6th Global Conference on Myositis (GCOM) meeting in March 2026. The clinical data, while not statistically significant, showed a trend toward slowing of disease progression relative to placebo as measured by IBMFRS in the overall patient population, including a 50% slowing of disease progression in a pre-defined analysis of less severe IBM patients with IBMFRS >29. Ulviprubart was also shown to have a favorable safety and tolerability profile compared to placebo. "The MUSCLE study provided encouraging data in a pre-defined analysis of patients with less severe disease, underscoring ulviprubart's unique mechanism of targeting highly differentiated cytotoxic T cells expressing KLRG1," said Namita Goyal, MD, Chief of the Neuromuscular Division at the University of California, Irvine School of Medicine. "IBM continues to be a disabling, progressive disease with no approved treatment, affecting tens of thousands of patients around the world. Ulviprubart demonstrated clear and meaningful slowing of disease progression in less severe disease, offering real hope to patients, care partners, and the physicians who treat them." "There is a significant unmet need for an approved treatment for IBM. The expertise and persistence of the Abcuro team to understand this disease and the role ulviprubart may have in targeting these cytotoxic T cells that are associated with muscle destruction was key to our continued investment of the company. We are excited to work closely with the company as it moves forward in this next chapter," said Ron Hunt, Co-Founder and Managing Director of New Leaf Venture Partners. About Ulviprubart Ulviprubart is a first-in-class, potent, monoclonal antibody that targets pathogenic T cells that express killer cell lectin-like receptor G1 (KLRG1) on their cell surface, referred to as KLRG1+ T cells. Ulviprubart is designed to selectively target and deplete well-differentiated cytotoxic KLRG1+ T cells where KLRG1 is highly expressed, while sparing other immune cells, which may offer improvements in safety and tolerability as compared to other T cell depleting approaches. About Inclusion Body Myositis (IBM) IBM is a rare, debilitating and relentlessly progressive chronic autoimmune muscle disease with no approved pharmacologic treatments and a significant unmet need. It is mediated by highly differentiated T cells that are chronically or aberrantly overstimulated and can have detrimental long-term effects including destruction of healthy muscle tissue. People living with IBM progressively lose muscle function, including loss of grip, dexterity and mobility. Based on published epidemiology literature, the ICD-10 code for IBM and an estimate for those misdiagnosed or undiagnosed, Abcuro estimate there are approximately 40,000 patients diagnosed with IBM in the United States and Abcuro estimate the prevalence of IBM to be approximately 35,000 patients across major European countries and Japan. Abcuro estimate that patients with less severe disease represent nearly 50% of the overall IBM patient population. About Abcuro Abcuro is a clinical stage biotechnology company developing potentially first-in-class immunotherapies designed to benefit people living with debilitating and progressive rare autoimmune diseases and for other indications where certain cytotoxic T cells are pathogenic. Abcuro believe that by selectively targeting and depleting highly cytotoxic T cells, which are key drivers of chronic inflammation and damage, Abcuro can advance its mission to deliver potentially life-transforming, disease-modifying therapies to patients facing these devastating conditions. The company's lead program, ulviprubart, is currently being evaluated in inclusion body myositis (IBM). For more information, visit Abcuro on LinkedIn and at abcuro.com.

Claris Bio
Jul 29th, 2026
07-28-2026 Press Releases from Claris Bio

Latest Press Releases from Claris Bio.

Fierce Healthcare
Jun 15th, 2026
InStride Health lands $30M series C to expand pediatric mental health services

InStride Health, a provider of virtual specialty mental healthcare for children and young adults, has raised $30 million in Series C funding led by Echo Health Ventures and FMZ Ventures. Existing investors including .406 Ventures, General Catalyst and Mass General Brigham Ventures also participated. Founded in 2021, InStride offers insurance-based treatment for anxiety and obsessive-compulsive disorder in patients aged seven to 24. The company pairs each patient with a care team comprising a psychiatrist, therapist and exposure coach, providing support through text and a mobile application. InStride has treated 5,000 patients across 17 states, primarily on the East Coast and Texas. The company published data showing 97% of patients demonstrated clinical improvement, with a 53% average reduction in anxiety scores. The funding will support expansion into new markets and strengthen payer partnerships.